All In Biotech

Drug Trial Radar · NCT07544160

BCMA-CD19 cCAR T for the Treatment of Refractory Inflammatory Bowel Disease (IBD)

A Single-arm, Open-label Phase I Clinical Study to Evaluate ICG318 CAR-T in Adults With Refractory Inflammatory Bowel Disease

Last checked: Nov 19, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Apr 7, 2026

Primary completion

Apr 7, 2028

Study completion Apr 7, 2028

Sponsor

Lead sponsor
iCell Gene TherapeuticsIndustry
Sponsor type
Industry
Collaborators
iCAR Bio Therapeutics Ltd.
First posted
Apr 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I, IIa, Single-Arm, interventional, open label, treatment study to evaluate the safety and tolerability of ICG318 CAR-T (BCMA-CD19-IL-15/IL15sushi cCAR T cells) in patients with relapsed and/or refractory inflammatory bowel disease.

Conditions

  • Inflammatory Bowel Diseases (IBD)

Interventions

  • ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR TBiological

    Anti-BCMA, Anti-CD19 Compound CAR-T cells

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Adverse Events (AEs) after ICG318 CAR-T infusion.Time frame: Starting day 0 and up to 2 years after ICG318 CAR-T infusion.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhongshan people's hospital

    Zhongshan, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.